Press release
Multiple Myeloma market across the 7MM was USD 21.3 billion in 2023, and it is anticipated to continue rising by 2034, estimates DelveInsight
Multiple Myeloma market
Request for a Free Sample Report @ https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Multiple Myeloma Market Report are:
• DelveInsight projects steady compound annual growth in the Multiple Myeloma market through 2034.
• In 2023, the Multiple Myeloma market across the 7MM was valued at roughly USD 21.3 billion, and it is anticipated to continue rising by 2034.
• Major companies active in the Multiple Myeloma treatment landscape include GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx Therapeutics), Takeda Pharmaceutical, Millennium Pharmaceuticals, Sanofi, Karyopharm Therapeutics, Janssen Biotech, AbbVie, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Precision BioSciences, Ichnos Sciences (Glenmark), Poseida Therapeutics, Molecular Partners, Chipscreen Biosciences, Nanjing Legend Biotech, Merck Sharp & Dohme, Regeneron Pharmaceuticals, Cartesian Therapeutics, AstraZeneca, MorphoSys/I-Mab Biopharma, among others.
• Prominent Multiple Myeloma therapies expected to enter the market include Venetoclax (ABT-199), Ciltacabtagene Autoleucel (cilta-cel/JNJ-4528/LCAR-B38M), REGN5458, Iberdomide (CC-220), Blenrep (Belantamab Mafodotin), Abecma (Idecabtagene vicleucel/bb2121), Pepaxto (melflufen), Sarclisa (Isatuximab), Xpovio (Selinexor), Darzalex (Daratumumab), and several others.
• In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5-25 mg), a treatment for multiple myeloma and certain cases of myelodysplastic syndromes (MDS). The product, bioequivalent to Bristol-Myers Squibb's Revlimid®, will be manufactured at Lupin's Pithampur facility in India.
• In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.
• In March 2025, the FDA issued its first untitled letter to Edenbridge Pharmaceuticals (now Dexcel Pharma) regarding a promotional panel for Hemady, following a Bad Ad complaint. The agency noted missing risk details and inadequate study information. Hemady is an oral 20 mg dexamethasone product designed to lower pill burden for Multiple Myeloma patients.
• In March 2025, the HealthTree Foundation launched an AI-powered Personalized Clinical Trial Finder to help Multiple Myeloma patients locate suitable clinical trials. Integrated into the HealthTree Cure Hub Registry, the tool uses individual medical histories to deliver more precise and efficient trial-matching.
• In February 2025, Opna Bio reported that its oral small-molecule inhibitor OPN-6602 received FDA Orphan Drug Designation for Multiple Myeloma. The therapy targets the EP300 and CBP proteins.
• On November 6, 2024, Nanjing Leads Biolabs announced that its bispecific T-cell engager LBL-034 designed to target GPRC5D and CD3 for Multiple Myeloma was granted Orphan Drug Designation by the U.S. FDA.
• In March 2024, Fate Therapeutics initiated a Phase I dose-finding trial of FT576, both as a standalone therapy and in combination with daratumumab for Multiple Myeloma. The study includes dose-escalation and expansion phases.
• In February 2024, Cartesian Therapeutics shared positive findings from a Phase I/IIa dose-escalation study evaluating Descartes-25, an allogeneic mesenchymal stem cell therapy engineered to secrete a bispecific protein and additional factors, in patients with relapsed or refractory Multiple Myeloma.
Multiple Myeloma Overview
Multiple myeloma is a malignant plasma cell disorder characterized by the uncontrolled growth of abnormal plasma cells in the bone marrow. These cancerous cells crowd out healthy blood cells and produce excessive monoclonal protein, leading to bone destruction, anemia, kidney dysfunction, and weakened immunity. The disease typically evolves from precursor conditions such as MGUS or smoldering myeloma. Common symptoms include bone pain, fatigue, recurrent infections, and hypercalcemia. Diagnosis involves blood tests, bone marrow biopsy, imaging, and assessment of monoclonal protein levels. Treatment options include immunomodulators, proteasome inhibitors, monoclonal antibodies, CAR-T therapies, and stem cell transplantation.
Learn more about Multiple Myeloma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Multiple Myeloma Market
In 2023, the multiple myeloma market size in the 7MM was about USD 21.3 billion and is projected to grow by 2034. The US accounted for USD 14.3 billion, with Germany leading the EU markets. In fourth-line and later settings, CAR-T therapies ABECMA and CARVYKTI generated approximately USD 828 million in the US in 2023, with revenues anticipated to increase as new CAR-T options enter the market.
The current multiple myeloma market features a wide array of treatment options, including proteasome inhibitors, immunomodulators, HDAC inhibitors, monoclonal antibodies, chemotherapy, corticosteroids, nuclear export inhibitors, CAR-T therapies, and bispecific antibodies across various lines of care. Historically, standard treatment relied on alkylating agents like melphalan and cyclophosphamide combined with corticosteroids, later strengthened by autologous stem cell transplantation.
Selinexor (XPOVIO), a first-in-class nuclear export inhibitor, received accelerated FDA approval in 2019 for heavily pretreated relapsed/refractory patients. Conversely, the EMA declined to renew Blenrep's conditional authorization in 2023 due to insufficient efficacy.
The relapsed/refractory landscape is rapidly evolving, driven by FDA-approved CAR-T therapies and a bispecific antibody, with more candidates expected by 2025 from companies such as Pfizer, Johnson & Johnson, Regeneron, Roche, AbbVie, and CARsgen.
The Multiple Myeloma market is driven by several factors, including the rising prevalence of the disease, increasing awareness among patients and healthcare providers, and significant advancements in therapeutic options such as immunotherapies, CAR-T cell therapies, and bispecific antibodies. Supportive regulatory initiatives, such as fast-track approvals and orphan drug designations, also encourage innovation and accelerate product availability.
However, the market faces notable barriers, including the high cost of novel therapies, limited accessibility in developing regions, and the complex management of relapsed and refractory cases. Additionally, safety concerns, treatment-related side effects, and the need for long-term efficacy data pose challenges to broader adoption, impacting patient outcomes and healthcare budgets.
According to DelveInsight, the Multiple Myeloma market in 7MM is expected to witness a major change in the study period 2020-2034.
Request a sample and discover more about the report offerings @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Multiple Myeloma Epidemiology
The Multiple Myeloma epidemiology section provides insights into the historical and current Multiple Myeloma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Multiple Myeloma market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Multiple Myeloma Epidemiology @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Multiple Myeloma Emerging Drugs Uptake
Mezigdomide (CC-92480) - Bristol Myers Squibb
Mezigdomide is a next-generation cereblon E3 ligase modulator with strong immunomodulatory and anti-cancer activity. By binding to cereblon, it alters E3 ligase function, promoting the degradation of key transcription factors, including those that suppress T-cell activity. The therapy is being studied across multiple clinical settings for newly diagnosed and relapsed/refractory multiple myeloma (NDMM and RRMM). A Phase III trial evaluating mezigdomide with carfilzomib and dexamethasone in second-line and later therapy started in January 2023. Bristol Myers Squibb anticipates the first regulatory approval between 2026 and 2027.
Linvoseltamab (REGN5458) - Regeneron
Linvoseltamab is a full-length BCMA×CD3 bispecific antibody that redirects T cells to attack myeloma cells. Developed using Regeneron's VelocImmune and VelociBi platforms, it is being assessed in a broad clinical program, including a Phase III confirmatory study for relapsed/refractory multiple myeloma (RRMM). Additional trials are underway in first-line therapy, high-risk smoldering myeloma, MGUS, and in combination with a CD38×CD28 bispecific antibody. In February 2024, the FDA granted priority review for linvoseltamab for RRMM patients previously treated with at least three therapies, with an expected decision date of August 22, 2024.
Multiple Myeloma Pipeline Development Activities
• MP0250: Molecular Partners AG
• CLR 131 (131-CLR1404): Cellectar Biosciences
• PBCAR269A: Precision BioSciences
• Encorafenib + Binimetinib: Pfizer (Array Biopharma)
• Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
• Descartes-11: Cartesian Therapeutics
• Chidamide (Epidaza): Chipscreen Biosciences
• Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
• TAK-079: Takeda
• Opdivo (Nivolumab): Bristol-Myers Squibb
• Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
• Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
• GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
• REGN5458: Regeneron Pharmaceuticals
• Imbruvica (Ibrutinib): AbbVie (Pharmacyclics) & Johnson & Johnson
• JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
• Venetoclax (ABT-199): AbbVie and Roche
• BL-8040: BioLineRx
• Cetrelimab (JNJ-63723283): Janssen Research & Development
• Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
• P-BCMA-101 CAR-T cells: Poseida Therapeutics
• ECT-001: ExCellThera
• Imfinzi (Durvalumab): AstraZeneca
Request for a sample report to understand more about the Multiple Myeloma pipeline development activities @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Multiple Myeloma Therapeutics Assessment
Major key companies are working proactively in the Multiple Myeloma Therapeutics market to develop novel therapies which will drive the Multiple Myeloma treatment markets in the upcoming years are GlaxoSmithKline (LSE: GSK), Bristol-Myers Squibb (NYSE: BMY), Bluebird bio (NASDAQ: BLUE), Oncopeptides AB (STO: ONCO), Secura Bio (private), Amgen (NASDAQ: AMGN), Takeda Pharmaceutical (TSE: 4502), Millennium Pharmaceuticals (subsidiary of Takeda Pharmaceutical, TSE: 4502), Sanofi (EPA: SAN), Karyopharm Therapeutics (NASDAQ: KPTI), Janssen Biotech (subsidiary of Johnson & Johnson, NYSE: JNJ), AbbVie (NYSE: ABBV), Janssen Pharmaceutical (subsidiary of Johnson & Johnson, NYSE: JNJ), Bristol-Myers Squibb Company (Celgene) (NYSE: BMY), RAPA Therapeutics (private), Pfizer (NYSE: PFE), Array Biopharma (acquired by Pfizer, formerly NASDAQ: ARRY), Cellectar Biosciences (NASDAQ: CLRB), BioLineRx (NASDAQ: BLRX), Aduro Biotech (acquired by Chinook Therapeutics, formerly NASDAQ: ADRO), ExCellThera (private), Precision BioSciences (NASDAQ: DTIL), Glenmark (Ichnos Sciences SA) (NSE: GLENMARK), Poseida Therapeutics (NASDAQ: PSTX), Molecular Partners (SWX: MOLN), Chipscreen Biosciences (SHE: 300122), Nanjing Legend Biotech (NASDAQ: LEGN), Merck Sharp & Dohme Corp. (subsidiary of Merck & Co., NYSE: MRK), Regeneron Pharmaceuticals (NASDAQ: REGN), Cartesian Therapeutics (private), AstraZeneca (LSE: AZN), MorphoSys AG (XETRA: MOR)/I-Mab Biopharma (NASDAQ: IMAB)., and others.
Learn more about the emerging Multiple Myeloma therapies & key companies @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Multiple Myeloma Report Key Insights
1. Multiple Myeloma Patient Population
2. Multiple Myeloma Market Size and Trends
3. Key Cross Competition in the Multiple Myeloma Market
4. Multiple Myeloma Market Dynamics (Key Drivers and Barriers)
5. Multiple Myeloma Market Opportunities
6. Multiple Myeloma Therapeutic Approaches
7. Multiple Myeloma Pipeline Analysis
8. Multiple Myeloma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Multiple Myeloma Market
Get the Detailed TOC of the Multiple Myeloma Market report here @ https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Myeloma market across the 7MM was USD 21.3 billion in 2023, and it is anticipated to continue rising by 2034, estimates DelveInsight here
News-ID: 4299240 • Views: …
More Releases from DelveInsight Business Research
Carotid Stenotic Scan Devices Market is projected to grow at a CAGR of 5.31% by …
DelveInsight's report, "Carotid Stenotic Scan Devices Market Insights, Competitive Landscape, and Market Forecast 2032," provides an in-depth examination of the current and future market landscape. It covers major product innovations, growth drivers, barriers, competitive activity, and emerging devices shaping the industry.
According to DelveInsight's latest assessment, the Carotid Stenotic Scan Devices market is gaining momentum due to the rising prevalence of vascular and cerebrovascular disorders, such as carotid stenosis, carotid artery…
Global Microbial Fermentation Technology Market Size is projected to grow at a C …
DelveInsight's analysis indicates that the microbial fermentation technology market is witnessing robust expansion, driven largely by the rising burden of chronic conditions such as cancer and an array of infectious diseases including HIV, hepatitis B and C, and influenza. Growing demand for advanced therapeutic modalities such as cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies is further accelerating market momentum. Additionally, innovations in synthetic biology and precision fermentation are…
Airway Management Devices Market is projected to reach USD 2.29 billion by 2032, …
DelveInsight's latest assessment indicates that the rising incidence of asthma, COPD, and other respiratory conditions coupled with an increase in surgical procedures and worsening global air quality is significantly boosting the need for advanced airway management devices. Additionally, improved awareness, earlier diagnosis of respiratory diseases, and the introduction of technologically enhanced products are further accelerating market expansion.
DelveInsight's report, "Airway Management Devices Market Insights, Competitive Landscape and Market Forecast 2032," provides…
Postpartum Depression Market Set to Grow Substantially Through 2034, DelveInsigh …
DelveInsight's "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Forecast
https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Multiple
Mango AI's Multiple Face Swap Video Tool Changes Multiple Faces Instantly
In today's digital world, creating eye-catching and unique content is essential for standing out. The ability to swap multiple faces in a single video opens up creative possibilities, whether for personalized content, comedy or parody videos, or engaging social media posts. Mango AI, developed by Mango Animate, is excited to announce the launch of its advanced multiple face swap video (https://mangoanimate.com/ai/multiple-face-swap-video) tool, which is designed to simplify the creation of…
Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market Size research report offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
Get a Sample Copy of the Report at - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/100386
Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by demyelination, inflammation, degenerative changes such as progressive brain and spinal cord atrophy and neuroaxonal…
Massive Multiple Input Multiple Output (MIMO) Market May Set New Growth Story
A Latest intelligence report published by MR Forecast with title "Global Massive Multiple Input Multiple Output (MIMO) Market Outlook to 2032. A detailed study accumulated to offer Latest insights about acute features of the Massive Multiple Input Multiple Output (MIMO) market. This report provides a detailed overview of key factors in the Global Massive Multiple Input Multiple Output (MIMO) Market and factors such as driver, restraint, past and current trends,…
Multiple Sclerosis Drugs Market - Progressing Towards a Cure: Advancing Multiple …
Newark, New Castle, USA: The "Multiple Sclerosis Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Multiple Sclerosis Drugs Market: https://www.growthplusreports.com/report/multiple-sclerosis-drugs-market/7983
This latest report researches the industry structure,…
Multiple Sclerosis Drugs Market - Empowering Resilience, Embracing Possibilities …
Newark, New Castle, USA - new report, titled Multiple Sclerosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Multiple Sclerosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Multiple Sclerosis Drugs market. The report offers an overview of…
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
